Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;52(1):115-138.
doi: 10.1016/j.gtc.2022.10.002. Epub 2022 Oct 7.

The Impact of COVID-19 Infection on Miscellaneous Inflammatory Disorders of the Gastrointestinal Tract

Affiliations
Review

The Impact of COVID-19 Infection on Miscellaneous Inflammatory Disorders of the Gastrointestinal Tract

Mitchell S Cappell et al. Gastroenterol Clin North Am. 2023 Mar.

Abstract

The novel coronavirus pandemic of COVID-19 has emerged as a highly significant recent threat to global health with about 600,000,000 known infections and more than 6,450,000 deaths worldwide since its emergence in late 2019. COVID-19 symptoms are predominantly respiratory, with mortality largely related to pulmonary manifestations, but the virus also potentially infects all parts of the gastrointestinal tract with related symptoms and manifestations that affect patient treatment and outcome. COVID-19 can directly infect the gastrointestinal tract because of the presence of widespread angiotensin-converting enzyme 2 receptors in the stomach and small intestine that can cause local COVID-19 infection and associated inflammation. This work reviews the pathopysiology, clinical manifestations, workup, and treatment of miscellaneous inflammatory disorders of the gastrointestinal tract other than inflammatory bowel disease.

Keywords: COVID-19; Gastrointestinal; Inflammation; Pandemic; SARS.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Schreiber M. What a million Covid dead means for the U.S.’s future. Scientific Am. Available at: www.scientificamerican.com March 29 2022. Accessed April 8, 2022.
    1. Parohan M., Yaghoubi S., Seraji A., et al. Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1416–1424. - PubMed
    1. Daniell H., Nair S.K., Esmaeili N., et al. Debulking SARS-CoV-2 in saliva using angiotensin converting enzyme 2 in chewing gum to decrease oral virus transmission and infection. Mol Ther. 2022;30(5):1966–1978. - PMC - PubMed
    1. de Sousa F.A.C.G., Paradella T.C. Considerations on oral manifestations of COVID-19. J Med Virol. 2021;93(2):667–668. - PMC - PubMed
    1. Barbato L., Bernardelli F., Braga G., et al. Surface disinfection and protective masks for SARS-CoV-2 and other respiratory viruses: A review by SIdP COVID-19 task force. Oral Dis. 2020;18:10. - PMC - PubMed

Substances